Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Oxford Biomedica plc    OXB   GB00BDFBVT43

OXFORD BIOMEDICA PLC

(OXB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Oxford Biomedica plc
Oxford BioMedica Plc is a gene and cell therapy company. The Company and its subsidiaries has developed lentiviral vector delivery platform (LentiVector), which the Company leverages to develop in vivo and ex vivo products both in-house and with partners. Its LentiVector delivery platform has created a portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, liver and central nervous system (CNS) disorders. The Company's product pipeline includes OXB-302, OXB-203, OXB-204 and OXB-103 and OXB-401 and addresses neurodegenerative and a range of cancers. The Company has also developed partnership with various pharmaceutical companies to develop potential gene and cell therapy products. Its partnered products include AXO-LENTI-PD, SAR 422459 and SAR421869.

Number of employees : 554 people.
Sales per Business
20182019Delta
GBP (in Million)%GBP (in Million)%
Platform55.0082.4%51.0079.6% -7.28%
Product11.7717.6%13.0620.4% +10.95%
Sales per region
20182019Delta
GBP (in Million)%GBP (in Million)%
Europe41.5462.2%46.6072.7% +12.18%
Rest of World25.2437.8%17.4627.3% -30.82%
Managers
NameAgeSinceTitle
John Andrew Dawson602008Chief Executive Officer & Executive Director
Roch Doliveux622020Non-Executive Chairman
Nick Page-2018Chief Operating Officer
Stuart Paynter472017Chief Financial Officer & Director
Kyriacos Mitrophanous, Dr.-2015Chief Scientific Officer
James Miskin, Dr.-2000Chief Technical Officer
Dmitry Zamoryakhin, Dr.-2019Chief Medical Officer
Andrew John William Heath, Dr.712011Deputy Chairman
Martin Henry Diggle572012Non-Executive Director
Stuart Henderson61-Deputy Chairman
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 82,185,673 68,824,992 83.7% 0 0.0% 83.7%
Shareholders
NameEquities%
M&G Investment Management Ltd. 11,563,240 14.1%
Vulpes Investment Management Pte Ltd. 10,713,616 13.0%
Novo Nordisk Fonden 7,750,000 9.43%
Hargreaves Lansdown Asset Management Ltd. 3,727,030 4.53%
Canaccord Genuity Wealth Ltd. 3,243,825 3.95%
S Shah 2,992,000 3.64%
Aviva Investors Global Services Ltd. 2,571,534 3.13%
Liontrust Asset Management PLC 2,501,993 3.04%
Brookfield Asset Management Inc. 2,261,346 2.75%
Banque Pictet & Cie SA 1,766,000 2.15%
Company contact information
Oxford Biomedica Plc
Windrush Court
Transport Way
Oxford, Oxfordshire OX4 6LT

Phone : +44.1865.783.000
Fax : +44.1865.783.001
Web : http://oxfordbiomedica.co.uk
Sector Bio Therapeutic Drugs
1st jan.Capitalization (M$)
OXFORD BIOMEDICA PLC22.48%847
GILEAD SCIENCES, INC.-6.63%75 487
REGENERON PHARMACEUTICALS53.33%60 234
VERTEX PHARMACEUTICALS-4.05%55 058
WUXI APPTEC CO., LTD.64.68%39 515
BEIGENE, LTD.83.27%27 421
GENMAB A/S50.39%23 222
BIONTECH SE154.90%20 893
HUALAN BIOLOGICAL ENGINEERING INC.98.35%15 640
ARGENX SE48.19%12 350
MYOKARDIA, INC.204.78%11 859
SAREPTA THERAPEUTICS, INC.6.79%10 776
NEUROCRINE BIOSCIENCES, INC.-10.20%8 936
ASCENDIS PHARMA A/S14.58%8 302
MIRATI THERAPEUTICS, INC.39.88%8 237
BIOCON LIMITED49.68%7 073
EXELIXIS, INC.23.89%6 733
ACCELERON PHARMA INC.106.30%6 393
PEPTIDREAM INC.-13.66%5 894
ARROWHEAD PHARMACEUTICALS, INC.-7.68%5 802
ULTRAGENYX PHARMACEUTICAL INC.115.15%5 400